Statkraft, and AstraZeneca have agreed to wind power deliveries to increase the renewable electricity supply in Sweden. The agreement is based on the commissioning of new wind farms.
Under the agreement, AstraZeneca, the biopharmaceutical company, commits to purchasing 200 gigawatt-hours per year for ten years from Europe’s largest renewable energy producer, equivalent to two terawatt-hours.
This corresponds to approximately 80 percent of the company’s total electricity needs at its research facility in Gothenburg and manufacturing facility in Södertälje.1
AstraZeneca in Sweden has been using 100 percent certified renewable energy for several years.
With the agreement with Statkraft, AstraZeneca will also be able to increase access to renewable energy in the community where it operates.
The three wind farms are in Strömstad and Årjäng, in Sweden’s bidding area 3 (SE3), where AstraZeneca’s research and manufacturing facilities are also situated.
The wind farms are owned by Rabbalshede Kraft, who will also be responsible for their operation.
AstraZeneca Transition to Green Energy
AstraZeneca is also working to reduce its electricity consumption in its Swedish operations.
The company, for example, has been recycling excess heat and optimizing humidity and temperature in its facilities.
“We want to contribute to the green transition in society. It is important for us to support initiatives that increase the availability of renewable energy. To successfully mitigate climate change, we must collaborate across different sectors and think beyond our own operations. Here we see an opportunity to contribute to the increase of renewable energy in society,” says Per Alfredsson, President AstraZeneca AB, Sweden
AstraZeneca is also aiming to cut its entire value chain footprint (Scope 3) by 2030 by half and achieve a 90% reduction by 2045 globally from a 2019 baseline.
AstraZeneca was one of the first seven corporations in the world to have their net zero aims validated by the Science-Based aims initiative’s Net Zero Corporate Standard.
“We are very pleased to support this ambitious initiative for a sustainable transition. This agreement confirms the role of Statkraft as a leading supplier of renewable energy to Nordic industries and our ambition to be a leading market integrator in the energy system”, says Hallvard Granheim, Executive Vice President Markets at Statkraft.
- Statkraft, ‘Statkraft and AstraZeneca sign agreement on wind power delivery’, 9 August 2023, https://www.statkraft.com/newsroom/news-and-stories/2023/statkraft-och-astrazeneca-skriver-avtal-om-vindkraftleverans/